| The role of small intestinal bacterial overgrowth in Parkinson's disease A Fasano, F Bove, M Gabrielli, M Petracca, MA Zocco, E Ragazzoni, ... Movement Disorders 28 (9), 1241-1249, 2013 | 357 | 2013 |
| The treatment of dystonic tremor: a systematic review A Fasano, F Bove, AE Lang Journal of Neurology, Neurosurgery & Psychiatry 85 (7), 759-769, 2014 | 135 | 2014 |
| The neurobiology of falls A Fasano, M Plotnik, F Bove, A Berardelli Neurological Sciences 33, 1215-1223, 2012 | 129 | 2012 |
| Rivastigmine as alternative treatment for refractory REM behavior disorder in Parkinson's disease R Di Giacopo, A Fasano, D Quaranta, GD Marca, F Bove, AR Bentivoglio Movement disorders 27 (4), 559-561, 2012 | 125 | 2012 |
| GBA‐Related Parkinson's Disease: Dissection of Genotype–Phenotype Correlates in a Large Italian Cohort S Petrucci, M Ginevrino, I Trezzi, E Monfrini, L Ricciardi, A Albanese, ... Movement Disorders 35 (11), 2106-2111, 2020 | 100 | 2020 |
| Long-term outcomes (15 years) after subthalamic nucleus deep brain stimulation in patients with Parkinson disease F Bove, D Mulas, F Cavallieri, A Castrioto, S Chabardès, S Meoni, ... Neurology 97 (3), e254-e262, 2021 | 91 | 2021 |
| Pisa syndrome in Parkinson disease: an observational multicenter Italian study M Tinazzi, A Fasano, C Geroin, F Morgante, R Ceravolo, S Rossi, ... Neurology 85 (20), 1769-1779, 2015 | 91 | 2015 |
| Impulsive-compulsive behaviors in parkin-associated Parkinson disease F Morgante, A Fasano, M Ginevrino, S Petrucci, L Ricciardi, F Bove, ... Neurology 87 (14), 1436-1441, 2016 | 77 | 2016 |
| Temporal discrimination in patients with dystonia and tremor and patients with essential tremor M Tinazzi, A Fasano, A Di Matteo, A Conte, F Bove, T Bovi, A Peretti, ... Neurology 80 (1), 76-84, 2013 | 63 | 2013 |
| Which patients discontinue? Issues on Levodopa/carbidopa intestinal gel treatment: Italian multicentre survey of 905 patients with long-term follow-up M Sensi, G Cossu, F Mancini, M Pilleri, M Zibetti, N Modugno, R Quatrale, ... Parkinsonism & related disorders 38, 90-92, 2017 | 57 | 2017 |
| COVID-19 pandemic and psychiatric symptoms: the impact on Parkinson's disease in the elderly D Janiri, M Petracca, L Moccia, L Tricoli, C Piano, F Bove, I Imbimbo, ... Frontiers in psychiatry 11, 581144, 2020 | 54 | 2020 |
| Predictors of long‐term outcome of subthalamic stimulation in Parkinson disease F Cavallieri, V Fraix, F Bove, D Mulas, M Tondelli, A Castrioto, P Krack, ... Annals of neurology 89 (3), 587-597, 2021 | 52 | 2021 |
| Retrospective evaluation of the dose equivalence of Botox® and Dysport® in the management of blepharospasm and hemifacial spasm: a novel paradigm for a … AR Bentivoglio, T Ialongo, F Bove, F De Nigris, A Fasano Neurological Sciences 33, 261-267, 2012 | 41 | 2012 |
| Dementia and subthalamic deep brain stimulation in Parkinson disease: a long-term overview F Bove, V Fraix, F Cavallieri, E Schmitt, E Lhommée, A Bichon, S Meoni, ... Neurology 95 (4), e384-e392, 2020 | 38 | 2020 |
| An Italian neurology outpatient clinic facing SARS-CoV-2 pandemic: data from 2,167 patients C Piano, E Di Stasio, G Primiano, D Janiri, M Luigetti, G Frisullo, ... Frontiers in Neurology 11, 564, 2020 | 36 | 2020 |
| Clinical and genetic characteristics of late-onset Huntington's disease M Oosterloo, EK Bijlsma, SM Van Kuijk, F Minkels, CEM de Die-Smulders Parkinsonism & related disorders 61, 101-105, 2019 | 27 | 2019 |
| 24-Hour infusion of levodopa/carbidopa intestinal gel for nocturnal akinesia in advanced Parkinson's disease L Ricciardi, F Bove, KJ Espay, F Lena, N Modugno, YY Poon, R Krikorian, ... Movement disorders: official journal of the Movement Disorder Society 31 (4 …, 2016 | 25 | 2016 |
| COVID-19 and parkinsonism: a critical appraisal F Cavallieri, V Fioravanti, F Bove, E Del Prete, S Meoni, S Grisanti, ... Biomolecules 12 (7), 970, 2022 | 22 | 2022 |
| Liquid melevodopa versus standard levodopa in patients with Parkinson disease and small intestinal bacterial overgrowth A Fasano, F Bove, M Gabrielli, E Ragazzoni, S Fortuna, A Tortora, ... Clinical Neuropharmacology 37 (4), 91-95, 2014 | 22 | 2014 |
| Iron chelation therapy to prevent the manifestations of aceruloplasminemia F Bove, A Fasano Neurology 85 (12), 1085-1086, 2015 | 21 | 2015 |
